| Trial ID: | L5522 |
| Source ID: | NCT04221399
|
| Associated Drug: |
Dwp16001
|
| Title: |
Type 2 Diabetes Patients With Renal Impairment
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes
|
| Interventions: |
DRUG: DWP16001|DRUG: DWP16001
|
| Outcome Measures: |
Primary: Maximum Plasma Concentration [Cmax], on Days 1 to 4 at selected time points|Concentration-time curve [AUC], on Days 1 to 4 at selected time points|Urine glucose (g/day), Cummulative by time, on Days -1 to 4|Concentration of serum glucose, on Days 1 to 4 at selected time points |
|
| Sponsor/Collaborators: |
Sponsor: Daewoong Pharmaceutical Co. LTD.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
35
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-01
|
| Completion Date: |
2020-10
|
| Results First Posted: |
|
| Last Update Posted: |
2020-01-09
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT04221399
|
